BIOCHEMICAL MECHANISMS OF AN RB-ASSOCIATED SP1 INHIBITOR

RB 相关 SP1 抑制剂的生化机制

• 批准号: 2330920
• 负责人: Robert Chiu
• 金额: $ 21.31万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-04-01 至 2000-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2330920
• 关键词: affinity chromatography; antiserum; cell cycle; cell free system; chemical binding; fusion gene; gel filtration chromatography; gel mobility shift assay; gene deletion mutation; gene expression; genetic promoter element; genetic transcription; immunoprecipitation; laboratory rabbit; molecular site; oncoproteins; protein purification; protooncogene; retinoblastoma protein; site directed mutagenesis; synchronous cell division; transcription factor; tumor suppressor genes

The retinoblastoma susceptibility gene product p105Rb (RB) is generally believed to be an important regulator in the control of cellular proliferation and in regulating the cell cycle. The biochemical mechanisms for RB's action remain unclear. The transforming properties of several DNA tumor virus oncoproteins are dependent, at least in part, on their ability to bind to RB and presumably to sequester RB from its cellular counterparts. Recent reports have suggested that RB directly interacts with three important transcription factors, E2F, ATF-2 and ElF- 1. With these, it is clear that RB binds a number of cellular proteins, which may be directly or indirectly involved in transcriptional regulation of a set of genes required for controlling cell growth. Indeed, Six cellular genes have been identified as targets of transcriptional regulation by RB. These results reveal a new mechanism by which RB constrains cellular proliferation. Recently, we have demonstrated that RB activates transcription of c-jun gene through the Spl binding site within the c-jun promoter. The mechanism by which RB stimulates Spl-mediated transactivation is liberation of Spl from an inhibitor, Spl-I. This exciting observation warrants further investigation. The specific objectives of this proposal are: l) To isolate and characterize the cellular factor(s) that mediate inhibition of Spl binding activity. 2.) To study biochemical mechanisms by generation of antisera against Spl inhibitor (Spl-I). 3.) To determine the molecular events leading to stimulation of Sp l -mediated transactivation by retinoblastoma gene product. 4.) To study whether Spl- I expression or its binding to RB is cell cycle dependent. These objectives can be accomplished by purification of protein by using heparin-agarose, gel filtration and affinity chromatography, CAT assay, gel retardation assays, deletion, linker scanning mutant and site- directed mutagenesis, bacterially expressed GST fusion proteins, cell- free transcription-translation system, immunoprecipitation, 32p- orthophosphate labeled cells and synchronized cells. The study of the molecular mechanisms of Spl-I as a cellular target for RB is critically important. The cloning of this Spl inhibitor will likely provide insight into its identity, function and regulation. We believe that this proposal will not only identify a biochemical function for RB, but also will have a significant impact on our understanding of a functional link between two distinct classes of oncoproteins, RB and c- Jun, that are involved in the control of cell growth, as well as defining a novel mechanism for the regulation of c-jun expression.

视网膜母细胞瘤易感基因产物p105Rb （RB）一般为